Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

AVTX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Avalo Therapeutics, Inc.NASDAQ: AVTX

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $19.63M (cash outflow) rose 49.3% year over year, ahead of the -216.1% change in trailing-twelve-month net income. Sequentially, it rose 43.1% from the prior quarter. Over 3 fiscal years it compounded at +23.4% a year.

Context

  • Net income amounted to 132642.4% of revenue in FY2025, up 124676.6 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 12 analysts of -$32.99M (-57.8%) for the fiscal year ending Dec 2026, a slowdown from the +122.8% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$19.63M+43.1% QoQ
Last fiscal yearDec 2025
-$78.26M+122.8% YoY
LTMMar 2026
-$84.74M-216.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+49.3%+22.4%-26.9 pp
1 year+122.8%-57.8%-180.6 pp
3-year CAGR+23.4%-25.5%-48.9 pp
5-year CAGR-21.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(78.26M) USD
Year-over-year change
-122.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How AVTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -216.1% is the lowest of 9, against a peer median of +0.2%.
  • Net income amounts to 143627.1% of revenue for AVTX, versus a peer median of 179.7%.
AVTX Competitors
Net Income for AVTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYRESpyre Therapeutics, Inc.LTM Sep 2026$263.86M USD+77.1%+22.8%291.6%
IMUXImmunic, Inc.LTM Mar 2026$104.29M USD+8.2%-6.9%—
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$84.74M USD-216.1%+23.4%143627.1%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$78.15M USD+141.3%-19.7%—
XNCRXencor, Inc.LTM Jun 2026$71.19M USD-60.8%+18.5%67.8%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$69.66M USD-46.5%-9.3%832.6%
IFRXInflaRx N.V.LTM Mar 2026€41.2M EUR-7.9%+14.1%140477.1%
QTTBQ32 Bio Inc.LTM Mar 2026$33.24M USD+155.6%—61.9%
ANABAnaptysBio, Inc.LTM Mar 2026$26.79M USD-81.0%—11.5%
ODTXOdyssey Therapeutics, Inc.—— ———
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding AVTX) —+0.2%+3.6%179.7%

Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(84.38M)(41.66M)(31.54M)(35.13M)(78.26M)
Depreciation & Amortization1.66M166K158K169K344K
Deferred Income Tax22K28K14K114K165K
Stock-Based Compensation8.17M7.55M3.48M5.85M13.62M
Change in Working Capital2.84M(60K)(9.24M)(4.71M)3.84M
Accounts Receivables1.12M2.88M1.78M(475K)0
Inventory(35K)18K20K00
Accounts Payables796K(487K)(2.44M)(163K)(146K)
Other Working Capital961K(2.47M)(8.61M)(4.07M)3.99M
Other Non-Cash Items794K7.22M6.46M(15.35M)8.83M
Operating Cash Flow(70.89M)(26.75M)(30.68M)(49.06M)(51.46M)
Capital Expenditures(113K)(95K)(158K)00
Acquisitions (Net)000356K0
Purchases of Investments0000(113.72M)
Sales of Investments000031.31M
Other Investing Activities0025K0690K
Investing Cash Flow(113K)(95K)(133K)356K(81.72M)
Debt Repayment32.9M(14.81M)(21.24M)00
Common Stock Issued71.93M107K46.22M115.63M15.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.93M067K60.22M(510K)
Financing Cash Flow106.76M(14.7M)25.04M175.85M14.59M
Effect of Forex Changes096K000
Net Change in Cash35.76M(41.45M)(5.77M)127.15M(118.59M)
Free Cash Flow(71.01M)(26.85M)(30.84M)(49.06M)(51.46M)

Avalo Therapeutics, Inc.

NASDAQ:AVTX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.